Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Other Non-Current Liabilities (2024)

Rein Therapeutics filings provide 1 years of Other Non-Current Liabilities readings, the most recent being $277000.0 for Q4 2024.

  • For the quarter ending Q4 2024, Other Non-Current Liabilities changed N/A year-over-year to $277000.0, compared with a TTM value of $277000.0 through Dec 2024, changed N/A, and an annual FY2024 reading of $277000.0, changed N/A over the prior year.
  • Other Non-Current Liabilities hit $277000.0 in Q4 2024 for Rein Therapeutics, up from $116000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $277000.0 in Q4 2024, with the low at $116000.0 in Q2 2024.